FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Color Colo	1. Name and Address of Reporting Person* <u>Ji Henry</u>				2. Issuer Name and Ticker or Trading Symbol Scilex Holding Co [SCLX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner								
City (State) (State) (Zip) Rule 10b5-1(c) Transaction Indication Check this box is indicate that a ternsaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or Written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or Written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or Written plan that is intended to satisfy the affirmative defense conditions of Rule 10t5-1(c), See Instruction or Written plan that is intended to Securities Securities Acquired (A) for Code Instruction or Written plan that is intended to Securities Securities Acquired (A) for C	' '	,	,	,								below) below)					pecify				
Street PALO ALTO CA 94303					4. If Amend	4. If Amendment, Date of Original Filed (Month/Day/Year)															
Common Stock D5/17/2024 P So,000(1) A So.8797(2)(3) So,070 I By BioVintage, Inc. (49(5)) Common Stock D5/17/2024 P So,000(1) A So.8797(2)(3) So,070 I By BioVintage, Inc. (49(5)) Common Stock D5/17/2024 Date Date Date Date Expiration of Page Conversion Security (Instr. 3) Comparison of Page Comparison		LTO CA	<u> </u>	4303									X Form filed by One Reporting Person Form filed by More than One Reporting					- 1			
Table - Non-Derivative Securities Acquired Disposed of Or Beneficially Owned	(City)	(Sta	ate) (Z	ľip)	Rule 10	Rule 10b5-1(c) Transaction Indication															
1. Title of Security (Instr. 3) 2. Transaction Date Execution Date, Executi												intend	ded to								
Date Month/Day/Year Execution Date, Month/Day/Year Month/Day/Year Execution Date, Month/Day/Year Month/Day/Year Execution Date, Month/Day/Year M		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Common Stock	Date			Date	Execution Date, T if any C		Transaction Code (Instr.						Securities Beneficially Owned			Form: Direct (D) or Indirect (I)		Indirect Beneficial Ownership			
Common Stock Common Stock Common Stock Common Stock Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Acquired (A) or Derivative Securities (Month/Day/Year) Security Security Security Securities Acquired (A) or Derivative Securities (Month/Day/Year) Amount of Securities S							Code	v	Amou	nt	(A) or (D)	Pri	ce	Tr	ansacti						
Common Stock Common Stock Common Stock Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) Price of Price of Price of Price of Price of Underlying Derivative Security (Instr. 3) A. Deemed (A) or Disposed of (D) (Instr. 4) (Instr. 4) Amount of Securities Securities Securities (A) or Disposed of (D) (Instr. 4) and 5) Amount of Securities Securities Securities Securities Securities Securities (Instr. 4) Securities Securitie	Common	Stock		05/17/2024			P		50,0	00(1)	A	\$0).8797 ⁽²⁾⁽³	3)	50,0	70	I		BioVintage,		
Common Stock Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise (Month/Day/Year) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise (Month/Day/Year) 2. Conversion or Exercise (Month/Day/Year) 3. Transaction Code (Instr. 4) 4. Transaction Code (Instr. 4) 5. Number of Expiration Date (Month/Day/Year) 6. Date Exercisable and Expiration Date (Month/Day/Year) 9. Number of Derivative Securities (Month/Day/Year) 9. Number of Derivative Securities (Month/Day/Year) 1. Title of Date (Instr. 4) 1. Title of Date (Instr. 5) 1. Title of Derivative Securities (Month/Day/Year) 1. Title of Date (Instr. 4) 1. Title of Date (Instr. 4) 1. Title of Or Disposed of (Instr. 4) 1. Title of Date (Instr. 4) 2. Amount of Securities (Instr. 5) 2. Amount of Derivative Securities (Instr. 4) 2. Transaction (Instr. 5) 2. Amount of Derivative Securities (Instr. 4) 2. Amount of Derivative Securities (Instr. 4) 3. Amount of Derivative Securities (Instr. 4) 4. Transaction (Instr. 4) 1. Number of Derivative Securities (Instr. 5) 2. Amount of Derivative Securities (Instr. 4) 3. Amount of Derivative Securities (Instr. 4) 4. Transaction (Instr. 4) 4. Title of Date (Instr. 4) 5. Number of Date (Instr. 4) 6. Date Expiration Date	Common	Stock													2,74	19	I		BioVintage,		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) Price of Derivative Security Secur	Common	Stock													305,2	273	D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security Security Security (Instr. 3) 2. Conversion or Exercise (Month/Day/Year) 3. Transaction Date Exercisable and Execution Date, if any (Month/Day/Year) 4. Transaction Date Expiration Date (Month/Day/Year) 5. Number of Securities (Month/Day/Year) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities (Instr. 5) 9. Number of Derivative Security (Instr. 5) Ownership Form: Direct (D) or Indirect (I) (Instr. 4) Ownership Form: Direct (D) or Indirect (I) (Instr. 4) Ownership (Instr. 4) 11. Nature Price of Derivative Securities (Instr. 5) Ownership Form: Direct (D) or Indirect (I) (Instr. 4) Amount of Number of Derivative Securities (Instr. 4) Amount of Number of Derivative Securities (Instr. 4) Amount of Number of Derivative Security (Instr. 4) Amount of Number of Derivative Security (Instr. 4) Date Expiration Date Expiration Date (Month/Day/Year) Amount of Number of Derivative Security (Instr. 4) Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Common	Stock													292,2	264	I				
1. Title of Derivative (Instr. 3) 1. Title of Derivative (Instr. 3) 1. Title of Derivative Security (Instr. 3) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 2. Conversion or Exercise (Month/Day/Year) 3. Transaction Date (Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 4. Transaction Date (Month/Day/Year) 5. Number of Expiration Date (Month/Day/Year) 9. Number of Derivative Security (Instr. 5) 9. Number of Derivative Security (Instr. 4) 10. Ownership Form: Direct (I) (Instr. 4) 11. Nature Amount of Securities (Month/Day/Year) 9. Number of Derivative Security (Instr. 5) 11. Nature Amount of Securities (Month/Day/Year) 12. Amount or Number of Amount of Securities (I) (Instr. 4) 13. Transaction Date Expiration Date (Month/Day/Year) 14. Amount of Securities (Month/Day/Year) 15. Number of Derivative Security (Instr. 5) 16. Date Exercisable and Expiration Date (Month/Day/Year) 17. Title and Amount of Securities (Month/Day/Year) 18. Price of Derivative Security (Instr. 5) 19. Number of Derivative Security (Instr. 4) 10. Ownership Or Indirect (I) (Instr. 4) 11. Nature Expiration Date Expiration Date (Month/Day/Year) 11. Nature Expiration Date Expirat	Common	Stock													5,64	10	I		By Spouse		
Derivative Security (Instr. 3) Price of Derivative Security Security Price of Derivative Security Security Securi																					
Date Expiration of	Derivative Security	derivative lecurity nor Exercise nstr. 3) Price of Derivative Pric		Transaction Code (Instr.	Transaction Code (Instr. Securi Acqui (A) or Dispo of (D) (Instr.		vative urities uired or oosed b) tr. 3, 4		ation Date			unt of rities rlying rative rity (Instr.	Derivativ Security (Instr. 5)		derivativ Securiti Benefici Owned Followin Reporte Transac	ve jest or Indian (I) (Insection(s)		hip D) ect	of Indirect Beneficial Ownership		
					or Nu Date Expiration of					or Number of											

- 1. Open market purchase by the reporting person of 50,000 shares of common stock, par value \$0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions over a range of sales prices.
- 2. Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on May 17, 2024 at prices ranging from \$0.8700 to \$0.8800 per share, inclusive. The amount reflected has been rounded to 4 decimal points.
- 3. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range.
- 4. On December 30, 2022, the Board of Directors of Sorrento Therapeutics, Inc. ("Sorrento") declared a stock dividend (the "Dividend") to all holders of record of its common stock as of the close of business on January 9, 2023, of 0.1410127 of a share of Common Stock for each one share of common stock, par value \$0.0001 per share, of Sorrento ("Sorrento Common Stock"). The reporting person wrote a put option in Sorrento Common Stock on August 26, 2022 (the "Put Option"), which was adjusted as a result of the Stock Dividend to relate to an aggregate of 19,500 shares of Sorrento Common Stock and 2,749 shares of Common Stock and to reflect a corresponding change to the exercise price of the Put Option to \$0.80268 per share of Sorrento Common Stock and \$8.6002 per share of Common Stock
- 5. (Continued from footnote 4) The Put Option settled on March 17, 2023 and resulted in the reporting person becoming entitled to receive 2,749 shares of Common Stock at a price of \$8.6002 per share of Common Stock, upon the expiration of the lock-up on such shares which is currently set to expire on September 30, 2024.
- 6. Shares are held in family trusts of which the reporting person is a co-trustee with his spouse.

/s/ Jaisim Shah, as Attorney-

05/17/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in	n this form are not required to respond	unless the form displays a currently valid	OMB Number.